ASCO 2020：11项中国研究工作入选口头报告，17项Poster报告

不受全球新近冠疫情制约，原定于5月29日~6月2日在芝加哥主办的American临床研究学就会（ASCO）学术就会议当年将首次以线上形式举办，这是现有最大规模的线上盛就会。今天，开就会的简介解答公布，共103个sessions，中就会国共有11项研究成果表现出色口头报告，17项表现出色Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

过氧化替尼或拉帕替尼加卡培他滨领域于HER2+心肌梗死白血病（PHOEBE）：一项III期随机次测试。

首站：心肌梗死白血病

所写：中就会国医学科学院诊所徐兵河研究成果员、马飞研究成果员，复旦大学另有诊所胡夕春研究成果员等

简介号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴病态白血病标准规范疗程后卡培他滨维持节奏化学治疗的III期次测试（SYSUCC-001）。

首站：白血病—均匀分布/区域/主要用途疗程

所写：中就会山大学防疫其中就会心君树森研究成果员等

简介号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用心肌梗死脑细胞的特异病态基本特征来预期脑细胞脊液中就会循环DNA检查的权重: 新近工具对抗老对手

首站：新近工具解决老原因

所写：郭美芹 郭德兰等

简介号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为中就会晚期线粒体恶病态肿瘤的一线疗程：一项新近开表单、随机、多其中就会心II/III期次测试。

首站：腹腔肠道恶病态肿瘤—腹腔膀胱、癌变和实乃

所写：重庆大学特罗斯季亚涅齐诊所毕锋研究成果员、中就会国国民解放军双十诊所秦叔逵研究成果员等

简介号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中就会国中就会晚期肝恶病态肿瘤病人阿帕替尼双线疗程：一项随机、疗效对照、结果表明III期研究成果

首站：腹腔肠道恶病态肿瘤—腹腔膀胱、癌变和实乃

所写：中就会国国民解放军双十诊所秦叔逵研究成果员、重庆大学特罗斯季亚涅齐诊所郭秋研究成果员等

简介号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

中就会晚期患病态卵巢恶病态肿瘤二次线粒体减灭术的一项随机III期次测试：SOC1 / SGOG-OV2。

简介：妇科恶病态肿瘤症

所写：复旦大学另有中就会山诊所臧荣余研究成果员等

简介：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈恶病态肿瘤根治病态胎盘切除术后主要用途疗程中就会的序贯放化学治疗对比另行前列腺癌或同步放化学治疗（STARS研究成果）：一项随机、对照、新近开表单的III期次测试。

开就会：妇科恶病态肿瘤症

所写：中就会山大学防疫其中就会心黄鹤研究成果员、刘继红研究成果员等

简介号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：主要用途吉非替尼对比化学治疗领域于可切除的EGFR凋亡的N1-N2期NSCLC-随机III期抗病毒的最终总体肉食动物统计分析。

简介：肺恶病态肿瘤—非小线粒体均匀分布-区域/小线粒体/其他胸部

所写：广东省国民诊所吴一龙研究成果员等

简介号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR凋亡无以转移非小线粒体肺恶病态肿瘤病人一线色氨酸蛋白激酶衍生物建立联系或不建立联系积极第一线均匀分布前列腺癌：III期新近开表单临床研究随机次测试（SINDAS）的中就会期结果（NCT02893332）。

简介：肺恶病态肿瘤-非小线粒体转移

所写：成都市国民诊所曾铭研究成果员等

简介：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序病态死亡-1（PD-1）的人源化IgG4抗病毒建立联系阿昔替尼领域于心肌梗死黏膜黑色素疣病人的Ib期研究成果的总肉食动物期和生物标志物统计分析。

简介：黑色素疣/皮肤恶病态肿瘤

所写：北京大学诊所郭军、盛锡楠研究成果员等

简介：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的稳定病态和结果：通用CAR-T线粒体首次化学物质次测试疗程患/难治病态T线粒体急病态淋巴线粒体白血病（r/r T-ALL）的稳定病态和。开就会：建立联系开发中就会的疗程技术-免疫疗程。所写：君后林等简介：3013贴纸：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在中就会晚期膀胱上皮线粒体线粒体恶病态肿瘤病人中就会的领域：一项随机的新近开表单II期次测试（ORIENT-2）。开就会：腹腔肠道恶病态肿瘤-腹腔膀胱恶病态肿瘤、癌变恶病态肿瘤和实乃道恶病态肿瘤所写：徐建明研究成果员等简介：4511贴纸：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D甲基化CAR-T线粒体对滋养母线粒体疣的遏止病态疗程开就会：中就会枢神经系统所写：代红久、孙斌、杨东、徐晖、朱毛毛、魏佳、姚旭东简介：2522贴纸。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在中就会晚期错配修复局限病态病人中就会的领域开就会：建立联系开发中就会的疗程学-免疫疗程所写：沈琳研究成果员等简介：3021贴纸。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART疗程患/难治病态ACUTE淋巴线粒体白血病/淋巴疣的唯一未化学物质抗病毒开就会: 建立联系开发病态疗程学-免疫疗程所写简介：张明志，白水等简介：3026贴纸: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 萨里替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度醯（T）建立联系应领域于中就会晚期也就是说疣病人的Ib期研究成果开就会：发展病态疗程学--化学键靶向本品和微生物学所写：龚继芳，沈琳研究成果员等简介：3523贴纸：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin建立联系紫杉醇和nedaplatin疗程患病态或心肌梗死膀胱上皮线粒体线粒体恶病态肿瘤（ESCC）病人的II期研究成果。开就会：腹腔肠道恶病态肿瘤-腹腔膀胱、癌变和实乃道恶病态肿瘤的研究成果所写：君志强，郭玉红，君德申，君凤华，任超，谭琼 君志强、郭玉红、君德深、君凤华、任超、谭琼简介：4522贴纸：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.开就会：腹腔肠道恶病态肿瘤-腹腔膀胱恶病态肿瘤、癌变恶病态肿瘤和实乃管恶病态肿瘤的双线疗程所写：宋艳等简介：4524贴纸：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种血液外体的环RNA线病态领域于初始活检时检查高等级恶病态肿瘤的血液外体的环RNA线病态：一项多其中就会心的回顾病态研究成果开就会：移行上皮细胞恶病态肿瘤症---恶病态肿瘤、睾丸恶病态肿瘤和恶病态肿瘤所写简介：Liaoyuan Li等简介：5522贴纸。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 均匀分布中就会晚期宫颈恶病态肿瘤并发化学治疗后的主要用途化学治疗开就会: 妇科恶病态肿瘤症所写简介： 郭珉珉等简介：6031贴纸：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼疗程胰脏滋养病态恶病态肿瘤的相关病态：基于ALTER01031次测试的统计分析。就会北京话：外周所写：天津市诊所用心研究成果员简介：6526贴纸。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼疗程后病人结尾的制约: ALTER01031的亚组统计分析开就会：外周所写：天津市诊所用心研究成果员简介：6527贴纸。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA统计分析预期I-IIIA期非小线粒体肺恶病态肿瘤（NSCLC）病人术后患: GASTO1035和GASTO1018的结果开就会：肺恶病态肿瘤-非小线粒体均匀分布-区域病态/小线粒体/小线粒体/其他胸科恶病态肿瘤症所写：Si-Yu Wang等简介：9023贴纸：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小线粒体肺恶病态肿瘤（NSCLC）中就会EGFR色氨酸蛋白激酶衍生物的新近型耐药系统开就会:肺恶病态肿瘤-非小线粒体心肌梗死肺恶病态肿瘤所写简介：姚昕，金大姐，满宇，欧名妓，宝珠，薛武，杨少，范敏 姚昕、金大姐、满宇、欧名妓、宝珠、薛武、杨绍、范敏简介：9528贴纸：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1次测试中就会中就会晚期黑色素疣总肉食动物的替代终点开就会：黑色素疣/皮肤恶病态肿瘤所写：聂润聪，袁书强，郭元芳，陈英波，周志伟 聂润聪、袁书强、郭元芳、陈英波、周志伟简介：10030贴纸：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼疗程患或心肌梗死病变恶病态骨病人的II期研究成果开就会： 肉疣所写：唐丽娜，牛晓辉，君震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、朝臣、蔡启庆、涂崇奇、范正福、杨瑶简介：11525贴纸。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评分安罗替尼在中就会晚期肉疣病人多线疗程中就会的稳定病态和。开就会：肉疣所写：姚伟涛，君家强，浙江余姚人，徐明，杜新近辉，田志浩，牛晓颖 姚伟涛、君家强、浙江余姚人、君鑫、杜鑫辉、田志超、牛晓英简介：11526贴纸：414